

List of Institutional IND Contacts

The purpose of this document is to provide Overall Principal Investigators and their research teams guidance on contacting their institutional representative for Investigational New Drug (IND) applications.

The Food and Drug Administration (FDA) applies the same rules regarding IND research to everyone. If you are planning to be an IND holder or have questions about the IND process, please consult with your institutional contact for INDs.

Institution	Contact
Beth Israel Deaconess Medical Center	Jonathan Dinsmore, PhD Director, BIDMC CCTO jdinsmor@bidmc.harvard.edu
Brigham and Women's Hospital	Emily Oullette QI Specialist, Partners QA/QI Program eoullette@partners.org
Children's Hospital Boston	Christina DiTomasso McCarthy, M.S. Senior Compliance and Reg Affairs Specialist Christina.mccarthy@childrens.harvard.edu
Dana-Farber Cancer Institute	Michele Copersino Assoc Director, Reg Affairs, DFCI CTO Michele_copersino@dfci.harvard.edu
Massachusetts General Hospital	Lauren Cohen Lead Regulatory Affairs Coordinator, MGH CCPO Lcohen16@mgh.harvard.edu